PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.November 20, 2025 7:00 AM EST | Source: PreveCeutical Medical Inc.NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Releases of September 4, 2025, September 19, 20 ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases of August 5, 2025, September 5, 2025 and October 10, 2025 it has closed a second tranche (the "Second Tranche") of its previously announced $1,200,000 non-brokered private placement (the " ...

融资活动 - 公司完成初始份额的非经纪私募配售 发行16,162,500份单位 每单位价格0.04加元 募集资金总额646,500加元[1] - 每单位包含1股普通股和0.5份认股权证 每份完整权证可认购额外股份 行权价0.06加元 有效期24个月[2] - 权证附有加速行权条款 当股价连续10个交易日达到或超过0.18加元时 公司可通过新闻公告将权证有效期缩短至公告后30天[2] 中介费用 - 公司向合格中介支付23,600加元现金及590,000份中介权证作为中介费用[3] - 中介权证行权价0.06加元 有效期24个月 同样适用加速行权条款[3] 资金用途 - 初始募集资金将用于支付应付账款 运营费用和一般营运资金需求[4] - 公司计划在未来数周内完成剩余100万加元配售额度的第二份额发行[4] 证券限制 - 初始份额发行的所有证券受四个月零一天禁售期限制 符合证券法规定[4] - 本次发行证券未且不会在美国证券交易委员会注册 不得在美国境内发行或销售[5] 公司业务 - 公司专注于健康科学领域 开发预防和治疗性有机及天然等同产品[6] - 研发管线包含五项计划：糖尿病与肥胖双基因疗法 Sol-gel项目 天然等同肽类药物 非成瘾性镇痛肽替代品 以及脑震荡治疗产品[6]